Matches in Nanopublications for { ?s ?p "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP630788.RAcvI5R4YUgcgjheJ7S3Egyo8RcJlTPk0rQiKTIKKNHVI130_assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP630788.RAcvI5R4YUgcgjheJ7S3Egyo8RcJlTPk0rQiKTIKKNHVI130_provenance.
- assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP636980.RAcXvgaMv-eoOtuMTYGsKZTXxjXHi0I02iqjHY4C-o42Q130_assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP636980.RAcXvgaMv-eoOtuMTYGsKZTXxjXHi0I02iqjHY4C-o42Q130_provenance.
- assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP762161.RANdcGpy9D4Zygv3YdufSOU97vgDBtq_rLsBVQQxAv-SM130_assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP762161.RANdcGpy9D4Zygv3YdufSOU97vgDBtq_rLsBVQQxAv-SM130_provenance.
- NP1053069.RAqO70uxniu6x4HteqvO6JbgARsRUqcypUgLXx3HSN2M8130_assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053069.RAqO70uxniu6x4HteqvO6JbgARsRUqcypUgLXx3HSN2M8130_provenance.
- NP368340.RAOUxgpthA1gk9y8lXBV5pPURWSXznJekp6l971kuvcIg130_assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368340.RAOUxgpthA1gk9y8lXBV5pPURWSXznJekp6l971kuvcIg130_provenance.
- NP1053071.RA2TMbEwnDkutNXlxgnSyKtkBecXHteY6Or72rGmCF7yg130_assertion description "[These results suggest that PPAR? agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053071.RA2TMbEwnDkutNXlxgnSyKtkBecXHteY6Or72rGmCF7yg130_provenance.